Venetoclax, azacitidine, and mitoxantrone for new AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with AML (or a related condition called MDS/AML with 10-20% blasts).
- You must be at least 14 years old.
- Your overall health must be fairly good (ECOG performance status 0-2, meaning you can care for yourself).
- Your liver, kidney, and heart function must be within certain limits (tests will be done to check).
- You cannot have certain genetic subtypes of AML (like APL or AML with specific fusion genes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent, as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works well and is safe.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.